Neogenomics (NEO) Equity Average (2011 - 2026)

Neogenomics (NEO) has reported Equity Average for 16 consecutive years, with $832.7 million the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at $832.7 million, down 7.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $832.7 million (down 7.0% YoY), and the FY2025 annual result was $869.5 million, down 5.69% from the prior year.
• Equity Average was $832.7 million for Q1 2026 at Neogenomics, down from $837.4 million in the prior quarter.
• Over five years, Equity Average peaked at $1.1 billion in Q1 2022 and troughed at $832.7 million in Q1 2026.
• Average Equity Average over 5 years is $940.3 million, with a median of $932.5 million recorded in 2024.
• The widest YoY moves for Equity Average: up 41.96% in 2022, down 10.44% in 2022.
• Over 5 years, Equity Average stood at $1.0 billion in 2022, then declined by 6.07% to $944.5 million in 2023, then slipped by 4.15% to $905.3 million in 2024, then slipped by 7.49% to $837.4 million in 2025, then decreased by 0.57% to $832.7 million in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $832.7 million in Q1 2026, $837.4 million in Q4 2025, and $846.2 million in Q3 2025.